Your Article Summary
See Latest ArticlesTaxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials
Journal of Clinical Oncology, 01/03/08
De Laurentiis M et al. - In a study to evaluate the efficacy, disease-free survival (DFS), and overall survival (OS) after incorporating taxanes into anthracycline-based regimens for early breast cancer (EBC), it was found that the addition of a taxane improves the DFS and OS of high-risk EBC patients
Methods- Studies were retrieved by searching the PubMed database and the proceedings of major conferences
- Hazard ratios (HR) and 95% CIs were extracted for DFS and OS from each trial and pooled estimates were obtained using an inverse-variance model
- 13 studies were included in the meta-analysis of 22,903 patients
- The pooled HR estimate was 0.83 for DFS and 0.85 for OS
- Risk reduction was not influenced by the type of taxane, by estrogen receptor (ER) expression, by number of axillary metastases, or by patient's age/menopausal status
- Sensitivity analysis showed that taxanes given in combination with anthracyclines did not significantly improve OS
- The test for interaction showed that HR did not differ between the 2 schedules
- Taxane administration resulted in an absolute 5-year risk reduction of 5% for DFS and 3% for OS
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
Annals of Internal Medicine, 11/17/09
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Vitamin D association with estradiol and progesterone in young women
Cancer Causes and Control, 11/23/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09